ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01877382
Recruitment Status : Recruiting
First Posted : June 13, 2013
Last Update Posted : March 8, 2018
Sponsor:
Information provided by (Responsible Party):
Daiichi Sankyo, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : April 2018
  Estimated Study Completion Date : July 2018